286 related articles for article (PubMed ID: 21821523)
41. Effect of inflammatory factor-induced cyclo-oxygenase expression on the development of reperfusion-related no-reflow phenomenon in acute myocardial infarction.
Jiao Q; Ke Q; Li W; Jin M; Luo Y; Zhang L; Yang D; Zhang X
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):162-70. PubMed ID: 25399887
[TBL] [Abstract][Full Text] [Related]
42. Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion.
Hale SL; Kloner RA
J Thromb Thrombolysis; 2015 Jan; 39(1):50-4. PubMed ID: 25017632
[TBL] [Abstract][Full Text] [Related]
43. Management of 'no-reflow' complicating reperfusion therapy.
Lee KW; Norell MS
Acute Card Care; 2008; 10(1):5-14. PubMed ID: 18449813
[TBL] [Abstract][Full Text] [Related]
44. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion.
Reffelmann T; Hale SL; Dow JS; Kloner RA
Circulation; 2003 Dec; 108(23):2911-7. PubMed ID: 14656914
[TBL] [Abstract][Full Text] [Related]
45. Delayed treatment with hypothermia protects against the no-reflow phenomenon despite failure to reduce infarct size.
Hale SL; Herring MJ; Kloner RA
J Am Heart Assoc; 2013 Jan; 2(1):e004234. PubMed ID: 23525431
[TBL] [Abstract][Full Text] [Related]
46. Myocardial no-reflow treatment.
Muller O; Trana C; Eeckhout E
Curr Vasc Pharmacol; 2013 Mar; 11(2):278-85. PubMed ID: 23506504
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.
Kobatake R; Sato T; Fujiwara Y; Sunami H; Yoshioka R; Ikeda T; Saito H; Ujihira T
Heart Vessels; 2011 Jul; 26(4):379-84. PubMed ID: 21110199
[TBL] [Abstract][Full Text] [Related]
48. Mechanism and potential treatment of the "no reflow" phenomenon after acute myocardial infarction: role of pericytes and GPR39.
Methner C; Cao Z; Mishra A; Kaul S
Am J Physiol Heart Circ Physiol; 2021 Dec; 321(6):H1030-H1041. PubMed ID: 34623177
[TBL] [Abstract][Full Text] [Related]
49. The no-reflow phenomenon in the coronary circulation.
Kiernan TJ; Ruggiero NJ; Bernal JM; Don CW; Witzke C; Kiernan GD; Cubeddu RJ; Yan BP
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):181-92. PubMed ID: 19689256
[TBL] [Abstract][Full Text] [Related]
50. Peri-interventional coronary vasomotion.
Gregorini L; Marco J; Heusch G
J Mol Cell Cardiol; 2012 Apr; 52(4):883-9. PubMed ID: 21971073
[TBL] [Abstract][Full Text] [Related]
51. Distal coronary embolization following acute myocardial infarction increases early infarct size and late left ventricular wall thinning in a porcine model.
Thomas RM; Lim SY; Qiang B; Osherov AB; Ghugre NR; Noyan H; Qi X; Wolff R; Ladouceur-Wodzak M; Berk TA; Butany J; Husain M; Wright GA; Strauss BH
J Cardiovasc Magn Reson; 2015 Dec; 17():106. PubMed ID: 26620277
[TBL] [Abstract][Full Text] [Related]
52. Coronary microvascular reperfusion injury and no-reflow in acute myocardial infarction.
Kang S; Yang Y
Clin Invest Med; 2007; 30(3):E133-45. PubMed ID: 17716552
[TBL] [Abstract][Full Text] [Related]
53. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives.
Galasso G; Schiekofer S; D'Anna C; Gioia GD; Piccolo R; Niglio T; Rosa RD; Strisciuglio T; Cirillo P; Piscione F; Trimarco B
Angiology; 2014 Mar; 65(3):180-9. PubMed ID: 23362304
[TBL] [Abstract][Full Text] [Related]
54. The significance of microthrombosis and fgl2 in no-reflow phenomenon of rats with acute myocardial ischemia/reperfusion.
Shao L; Wu D; Zhang P; Li W; Wang J; Su G; Liao Y; Wang Z; Liu K
Clin Appl Thromb Hemost; 2013; 19(1):19-28. PubMed ID: 22387586
[TBL] [Abstract][Full Text] [Related]
55. [No-reflow: update on diagnosis, pathophysiology and therapeutic strategies].
Montone RA; Camilli M; Del Buono MG; Meucci MC; Gurgoglione F; Russo M; Crea F; Niccoli G
G Ital Cardiol (Rome); 2020 Jun; 21(6 Suppl 1):4S-14S. PubMed ID: 32469339
[TBL] [Abstract][Full Text] [Related]
56. No-reflow phenomenon in the heart and brain.
Kloner RA; King KS; Harrington MG
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H550-H562. PubMed ID: 29882685
[TBL] [Abstract][Full Text] [Related]
57. Reduction of "no-reflow" phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study.
Amado LC; Kraitchman DL; Gerber BL; Castillo E; Boston RC; Grayzel J; Lima JA
J Am Coll Cardiol; 2004 Apr; 43(7):1291-8. PubMed ID: 15063444
[TBL] [Abstract][Full Text] [Related]
58. CMR of microvascular obstruction and hemorrhage in myocardial infarction.
Wu KC
J Cardiovasc Magn Reson; 2012 Sep; 14(1):68. PubMed ID: 23021401
[TBL] [Abstract][Full Text] [Related]
59. Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention.
Gao MD; Zhang EY; Liu YY; Li XW; Xiao JY; Sun GY; Liu Y
Chin Med J (Engl); 2020 Apr; 133(7):766-772. PubMed ID: 32149760
[TBL] [Abstract][Full Text] [Related]
60. State of the Art: No-Reflow Phenomenon.
Caiazzo G; Musci RL; Frediani L; Umińska J; Wanha W; Filipiak KJ; Kubica J; Navarese EP
Cardiol Clin; 2020 Nov; 38(4):563-573. PubMed ID: 33036718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
